Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A | P37088 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916348 | 0.97 | SCNN1A (0.94) | SCNN1A | |
| Hydrochloric Acid SCHEMBL937636 | 0.89 | SCNN1A (0.79) | SCNN1A | |
| SCHEMBL938374 | 0.86 | SCNN1A (0.75) | SCNN1A | |
| SCHEMBL5671579 | 0.86 | SCNN1A (0.86) | SCNN1A | |
| SCHEMBL15092805 | 0.86 | SCNN1A (0.75) | SCNN1A | |
| SCHEMBL1996614 | 0.86 | SCNN1A (0.75) | SCNN1A | |
| 552-02 Free Base SCHEMBL9913774 | 0.83 | SCNN1A (0.71) | SCNN1A | |
| 552-02 Free Base SCHEMBL9913757 | 0.83 | SCNN1A (0.71) | SCNN1A | |
| 552-02 Free Base SCHEMBL2015162 | 0.83 | SCNN1A (0.71) | SCNN1A | |
| SCHEMBL19361273 | 0.82 | SCNN1A (0.69) | SCNN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332151-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2025-10-30 | — | — | US | claimed |
| CN-119947720-A | Methods of treating cystic fibrosis | 弗特克斯药品有限公司 | 2025-05-06 | — | — | CN | claimed |
| EP-4525858-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2025-03-26 | — | — | EP | claimed |
| WO-2023224931-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-23 | — | — | WO | claimed |
| EP-4247817-A1 | MACROCYCLES CONTAINING A 1,3,4-OXADIAZOLE RING FOR USE AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116670140-A | Macrocyclic compounds containing 1,3, 4-oxadiazole rings as modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | claimed |
| US-20230099745-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2023-03-30 | — | — | US | claimed |
| CN-113956648-B | High-strength silicate/polyurethane urea-based composite reinforcing material and preparation method thereof | 山西凝固力新型材料股份有限公司 | 2023-02-03 | — | — | CN | claimed |
| WO-2022109573-A1 | MACROCYCLES CONTAINING A 1,3,4-OXADIAZOLE RING FOR USE AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-05-27 | — | — | WO | claimed |
| CN-109475552-B | Methods and compositions for appetite control and weight management | 上海药苑生物科技有限公司 | 2022-04-05 | — | — | CN | claimed |
| CN-113956648-A | High-strength silicate/polyurethane urea-based composite reinforcing material and preparation method thereof | 山西凝固力新型材料股份有限公司 | 2022-01-21 | — | — | CN | claimed |
| US-20250332151-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250221971-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2025-07-10 | — | — | US | disclosed |
| US-12324802-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250179091-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-06-05 | — | — | US | disclosed |
| EP-3183021-A1 | FLUID RESERVOIR FOR AN AEROSOL GENERATOR AND AEROSOL GENERATOR COMPRISING THE FLUID RESERVOIR | PARI Pharma GmbH (DE) | 2017-06-28 | — | — | EP | disclosed |
| EP-3127616-A1 | METHOD OF MANUFACTURING A VIBRATABLE HEAD FOR AN AEROSOL GENERATOR AND VIBRATABLE HEAD FOR AN AEROSOL GENERATOR | PARI Pharma GmbH (DE) | 2017-02-08 | — | — | EP | disclosed |
| WO-2016026802-A1 | FLUID RESERVOIR FOR AN AEROSOL GENERATOR AND AEROSOL GENERATOR COMPRISING THE FLUID RESERVOIR | PARI PHARMA GMBH (DE) | 2016-02-25 | — | — | WO | disclosed |
| EP-2194966-B1 | AEROSOLS FOR SINUNASAL DRUG DELIVERY | PARI PHARMA GMBH (DE) | 2015-12-02 | — | — | EP | disclosed |
| WO-2011073662-A1 | COMBINATION OF A BENZOXAZINONE AND A FURTHER AGENT FOR TREATING RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221971-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, SLC26A4, SLC26A3 | SCNN1A 11/4885 |
| US-20250332151-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, SLC26A4, SLC26A3 | SCNN1A 12/4885 |
| US-20250179091-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | SCNN1A 5/4885 |
| US-12324802-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1G, SCNN1B | SCNN1A 5/4885 |
| US-20230099745-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | SCNN1A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.